Recombinant rhabdovirus containing a heterologous fusion protein
CA 2316033 A1 · Owner: Whitt, Michael A. · Inventors: Robison, Clinton S.; Whitt, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a composition comprising a recombinant or genetically engineered Rhabdovirus that expresses a Fusion Protein such as , the F protein of the Paramyxovirus SV5 strain. This recombinant Rhabdovirus may express other non-Rhabdovirus attachment proteins and/or an enhancer protein. The invention also relates to methods of making recombinant Rhabdoviruses which express an F Protein. These recombinant compositions can be used for purposes of research, as well as for diagnostic and therapeutic compositions for treatment of diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 22, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 22, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 22, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.